About
We aim to improve outcome for patients with solid cancer, particular for targeted- and immunotherapies, by use of more accurate and novel molecular diagnostics.
Research group leader
dr. Niven Mehra
With our bench-to-bedside approach, based on patient-focused aims, we will:
These aims will lead to more accurate genotyping of solid cancers, prediction of outcome and toxicity and response assessment.
Other aims are harrmonising tissue and data collection in biobanks in Radboud university medical center and within OncoOost, and translate findings towards trials including health-technology assessment.
Welcome to Research
We aim to improve outcome for patients with solid cancer, particular for targeted- and immunotherapies, by use of more accurate and novel molecular diagnostics.
dr. Niven Mehra
This website uses cookies. Read more about cookies.